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Inflammatory bowel disease and colorectal cancer:
the role of microbiota
· Inflammatory bowel disease (IBD) is a chronic intermittent disorder characterized by 
intestinal inflammation. 
· IBD patients have a higher risk of developing colorectal cancer (CRC).
· Intestinal microbiota is presumed to play a large role in IBD and CRC pathogenesis.
· Intestinal microbiota could contribute IBD-related CRC. 
Objectives
The aim of this review is to describe the role of intestinal microbiota in IBD-related CRC 
and to present molecular mechanisms whereby microbiota could drive carcinogenesis. 
VARIATIONS IN INTESTINAL MICROBIOTA TUMORIGENESIS DRIVING DYSBIOSIS
Figure 1. Factors involved in IBD-related CRC progression.
Figure 3. Increased/decreased bacterial species in IBD and their role in colitis and tumorigenesisFigure 2. On the left, most frequent variations in intestinal microbiota of IBD and CRC patients; on the right, shared microbial pattern between IBD and CRC.






· IBD patients have a protumoral microbial pattern that brings CRC susceptibility.
· Microbiota seems to contribute IBD-derived CRC, but it may not play the main role.
· ETBF and F. nucleatum seem to be more related to tumorigenesis initiation.
· AIEC mainly promotes colitis exacerbation and has a slight effect in tumorigenesis.
· Synergistic effect of microbiota, combined with other factors, could drive IBD-related CRC.
CONCLUSIONS
· Monitoring IBD patients microbiota could help us understand the role of microbiota in IBD-related CRC, 
especially in those patients who develop CRC.
· Pathobionts could be potential prognosis markers and therapeutic targets in both IBD and CRC.
FUTURE PERSPECTIVES
References
1. Svrcek M, et al. Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role of
Inflammation. J Crohn’s Colitis. 2018; 12(12):1486-198.
2. Chia-Hui Yu L. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground
hypothesis. J Biomed Sci. 2018;25(1):79.
3. Chung L, et al. ETBF Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe.
2018;23(3):421.
4. Yang Y, et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like
Receptor 4 Signaling to Nuclear Factor−κB, and Up-regulating Expression of MicroRNA-21. Gastroenterology. 2017;152(4):851-866.
Figure 4. ETBF induced mechanisms involved in colitis and tumorigenesis initiation Figure 5. F. nucleatum role in tumorigenesis. IκB: inhibitor of κB; IKK: IκB kinase. Adapted from Yang Y, et al. Figure 6. AIEC role in colitis chronification and its contribution to tumorigenesis initiation
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